BioTrace Medical is closing in on its $3.5 million goal, having raised $3.4 million in a funding round, according to a regulatory filing.
BioTrace, which is backed by early-stage medtech angel Xandex Investments, is developing a temporary cardiac pacing device to treat reversible symptomatic bradycardia.
San Mateo, Calif.-based BioTrace counts medical device legend Dr. Thomas Fogarty, inventor of the embolectomy catheter, as a member of its board, according to a regulatory filing.
BioTrace raised more than $3.4 million in the equity round from 6 unnamed investors, according to the filing.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.